/* global window */ /* ========================================================= ATLAS DATA — the ImmunoShield Demand Discovery session, seeded as evidence. Sourced from the P1–P7 working notes. ========================================================= */ const LOCATIONS = [ { id: "observatory", idx: "I", roman: "01", phase: "Listening", name: "The Observatory", coord: "FIELD 01 · 51.477° N", prompt: "What are we hearing — before we decide what it means?" }, { id: "cartographer", idx: "II", roman: "02", phase: "Framing", name: "The Cartographer’s Table", coord: "FIELD 02 · 48.858° N", prompt: "Which observations belong together — and what challenge do they describe?" }, { id: "horizon", idx: "III", roman: "03", phase: "Envisioning", name: "The Horizon Room", coord: "FIELD 03 · 64.135° N", prompt: "If this future became true, what would be different?", dark: true }, { id: "iceberg", idx: "IV", roman: "04", phase: "Assumptions", name: "The Iceberg Archive", coord: "FIELD 04 · 78.221° N", prompt: "What must be true that we are currently taking for granted?" }, { id: "river", idx: "V", roman: "05", phase: "Transformation", name: "The River Crossing", coord: "FIELD 05 · 45.502° N", prompt: "What must change, what must remain, and what disappears?" }, { id: "pass", idx: "VI", roman: "06", phase: "Crux", name: "The Mountain Pass", coord: "FIELD 06 · 46.534° N", prompt: "Which single challenge, if solved, unlocks the rest?" }, { id: "constellation", idx: "VII", roman: "07", phase: "Integration", name: "The Constellation Chamber",coord: "FIELD 07 · 27.988° N", prompt: "What now feels obvious that wasn’t obvious before?", dark: true }, ]; /* ---------- OBSERVATORY · Listening ---------- */ const LISTENING = { intro: "Field notes pinned to the wall. Picked up from the deck, the site, and Matthew’s outreach. Not yet organized. Not yet interpreted.", notes: [ { id: "n1", src: "DECK · SLIDE 04", kind: "quote", coord: "Q-01", body: "A cure for some — not for most.", prov: ["heard in listening"] }, { id: "n2", src: "DECK · THESIS", kind: "quote", coord: "Q-02", body: "Winning ≠ best cells alone. Winning = working therapy in a better product format.", prov: ["heard in listening"] }, { id: "n3", src: "DECK · MARKET", kind: "stat", coord: "S-01", body: "Only ~300K of 1.8M U.S. T1D patients are eligible today. 80% are disqualified by immune-suppression risk.", prov: ["heard in listening"] }, { id: "n4", src: "SITE · ACCESS", kind: "stat", coord: "S-02", body: "Immune rejection limits access to ~20% of patients. Removing the barrier could expand the market 5×.", prov: ["heard in listening"] }, { id: "n5", src: "DECK · POSITION", kind: "quote", coord: "Q-03", body: "An enabling player, not another full-stack cell bet.", prov: ["heard in listening"] }, { id: "n6", src: "DECK · STRATEGY", kind: "quote", coord: "Q-04", body: "The category is de-risked. The product model is not.", prov: ["heard in listening"] }, { id: "n7", src: "DECK · PIPELINE", kind: "quote", coord: "Q-05", body: "One company, two linked programs.", prov: ["heard in listening"] }, { id: "n8", src: "OBSERVATION", kind: "signal", coord: "O-01", body: "Safety is the wedge. Retrievability matters because reversibility lowers fear — for regulators, clinicians, investors, patients.", prov: ["heard in listening"] }, { id: "n9", src: "SITE · GTM", kind: "quote", coord: "Q-06", body: "ImmunoShield is uniquely positioned to make competitors into potential cell-therapy partners.", prov: ["heard in listening"] }, { id: "n10", src: "OBSERVATION", kind: "signal", coord: "O-02", body: "Manufacturing is not a back-office issue. It is central to the value proposition.", prov: ["heard in listening"] }, { id: "n11", src: "EMAIL · MATTHEW", kind: "quote", coord: "Q-07", body: "Raise against de-risked milestones rather than promise alone.", prov: ["heard in listening"] }, { id: "n12", src: "OBSERVATION", kind: "signal", coord: "O-03", body: "T1D is the beachhead, not the boundary. The platform is described as disease-agnostic.", prov: ["heard in listening"] }, ], prompts: ["What surprises us?", "What feels important?", "What doesn’t fit?"], reflect: "What we hear is that ImmunoShield is not trying to build a better encapsulation device. It is trying to solve the productization problem in allogeneic cell therapy — protected, retrievable, scalable, partner-ready, and eventually free of chronic immune suppression.", }; /* ---------- CARTOGRAPHER · Framing ---------- */ const FRAMING = { intro: "The notes return as objects. We don’t cluster everything at once. We make local decisions — two at a time — and let groups emerge.", pairs: [ { id: "p1", a: { src: "Q-03", text: "An enabling player, not another full-stack cell bet." }, b: { src: "Q-06", text: "Make competitors into potential cell-therapy partners." }, belong: true, because: "Both describe a position, not a product: value accrues to the enabling layer, and rivals become the customer base." }, { id: "p2", a: { src: "S-01", text: "300K of 1.8M eligible — 80% disqualified by immune suppression." }, b: { src: "Q-02", text: "Winning = working therapy in a better product format." }, belong: true, because: "Eligibility is a product-format problem, not a cell-quality problem. The format is what expands the funnel." }, { id: "p3", a: { src: "O-01", text: "Retrievability lowers fear for regulators and investors." }, b: { src: "Q-07", text: "Raise against de-risked milestones rather than promise." }, belong: true, because: "Both are about removing uncertainty. Value is created by de-risking, not by claims." }, { id: "p4", a: { src: "Q-05", text: "One company, two linked programs." }, b: { src: "S-02", text: "Removing the barrier could expand the market 5×." }, belong: false, because: "A pipeline-structure note and a market-sizing note point at different questions. Keep them apart for now." }, ], problems: [ { n: "01", title: "The access problem", text: "Allogeneic cell therapies can cure — but immune suppression disqualifies most patients. How do we expand eligibility from a small high-risk group to the broader disease population?", visible: true }, { n: "02", title: "The productization problem", text: "The cells are becoming good enough. The bottleneck is protection, delivery, manufacturing, retrievability, immune management. Not “who has the best cells” but “who turns good cells into scalable products.”", visible: true }, { n: "03", title: "The partner-adoption problem", text: "Even if it works scientifically, partners must choose to adopt it. How do we become easier to adopt than building a competing solution internally?", visible: false }, { n: "04", title: "The platform-credibility problem", text: "We ask partners to believe protection, tolerance, retrievability, and manufacturing matter — before human proof exists. How much evidence makes us infrastructure rather than experiment?", visible: false }, ], visibleChallenge: "How do we eliminate immune suppression from allogeneic cell therapies?", deeperChallenge: "How do we become the indispensable enabling layer in an emerging cell-therapy ecosystem — before larger players solve the same problem internally?", }; /* ---------- HORIZON · Envisioning ---------- */ const ENVISIONING = { intro: "A dark room. Three possible futures sit on the horizon as distant lights. Each expands when you approach it.", futures: [ { id: "f1", label: "Therapeutic company", bearing: "BEARING 312°", line: "Build a T1D cell therapy end-to-end.", consequences: ["Highest control over outcome.", "Highest capital requirement.", "Slowest path to value.", "You compete with Vertex, Sana, Lilly head-on."], verdict: "High control, high burn." }, { id: "f2", label: "Device / platform company", bearing: "BEARING 047°", recommended: true, line: "Lead with spiral macroencapsulation.", consequences: ["Win through protection, retrievability, manufacturability, partner fit.", "Lower capital, faster to a fundable inflection.", "Competitors can become customers.", "Near-term value driver with a clear wedge."], verdict: "The clearest, most fundable vision." }, { id: "f3", label: "Full immune-tolerance platform", bearing: "BEARING 184°", line: "Push pregnancy-inspired tolerance as the core.", consequences: ["Potentially the largest prize.", "More biologically and clinically complex.", "Asks partners to believe the whole thesis early.", "Best held as longer-term upside."], verdict: "The upside — not the wedge." }, ], vision: "ImmunoShield wins when the industry stops asking, “Can they build a cell therapy?” and starts asking, “Which cell therapies become more viable if they use ImmunoShield?”", signals: [ "A pharma or cell-therapy company funds feasibility work.", "A partner supplies cells for platform testing.", "FDA feedback clarifies the approval path.", "Large-animal data supports safety, function, retrievability.", "Financing shifts from belief to milestone.", ], }; /* ---------- ICEBERG · Assumptions ---------- */ const ASSUMPTIONS = { intro: "Each idea floats above the waterline. Pull it down to surface the assumption it rests on — and the counterfactual that would sink it.", items: [ { id: "a1", idea: "Immune suppression is the decisive adoption bottleneck.", assumption: "Partners rank immune suppression above efficacy, durability, CMC, reimbursement, and surgical burden.", counter: "Partners care more about efficacy or reimbursement.", test: "Interview 10 pharma/biotech buyers. Force-rank the adoption blockers.", weight: "HIGHEST" }, { id: "a2", idea: "Partners want an enabling layer, not another full-stack therapy.", assumption: "Cell-therapy developers would rather license protection than own it internally.", counter: "Partners prefer to build delivery and protection in-house.", test: "Ask target accounts: license, co-develop, build, acquire, or ignore?", weight: "HIGHEST" }, { id: "a3", idea: "Manufacturing fit is a differentiator.", assumption: "CMC teams see hydrogel injection molding as transferable to their process.", counter: "CMC teams see it as another process risk.", test: "Independent CMC audit → partner-facing process map + top-5 gaps.", weight: "HIGH" }, { id: "a4", idea: "The FDA path is manageable.", assumption: "Combination-product questions won’t add major time or evidence burden.", counter: "Combination-product uncertainty delays partner adoption.", test: "Prepare an INTERACT question package; seek early FDA feedback.", weight: "HIGH" }, { id: "a5", idea: "NHP data will unlock partner confidence.", assumption: "Large-animal endpoints are decision-grade for partners, not just scientifically positive.", counter: "Data proves science but not adoption.", test: "Pre-align NHP endpoints with 3 partners before study lock.", weight: "HIGH" }, { id: "a6", idea: "Partners will pay for feasibility.", assumption: "$150–250K partner-readiness sprints are sellable today.", counter: "They praise the science but wait for more data.", test: "Offer the priced package. Record: accept, reject, or re-scope.", weight: "MEDIUM" }, ], framing: "The riskiest assumptions are not scientific. They sit at the junction of partner behavior, CMC adoption, regulatory interpretation, and milestone financing.", }; /* ---------- RIVER · Transformation (placeholder, on-thesis) ---------- */ const TRANSFORMATION = { placeholder: true, intro: "Two banks. Today on the near side, tomorrow on the far. We place what crosses, what stays, and what is left behind. The bridge is the transformation itself.", today: { label: "TODAY — THE NEAR BANK", items: [ "Judged as a science company.", "Value measured by the quality of the cells.", "A promising preclinical device.", "Raising against the story.", ]}, tomorrow: { label: "TOMORROW — THE FAR BANK", items: [ "Judged as partner-ready infrastructure.", "Value measured by risk removed for the partner.", "The operating layer that makes good cells viable products.", "Raising against de-risked milestones.", ]}, bridge: [ { q: "What must change?", a: "The unit of value — from the elegance of the device to the behavior of a partner. Evidence must become decision-grade, not just positive." }, { q: "What must remain?", a: "Scientific credibility, retrievability as the safety wedge, and the disease-agnostic ambition underneath T1D." }, { q: "What disappears?", a: "“Praise as progress.” The full-stack temptation. Selling the whole platform before the wedge is proven." }, ], note: "Transformation has no working note from this session yet — this bank is staged as placeholder and is one of the steps the facilitator may activate live.", }; /* ---------- PASS · Crux ---------- */ const CRUX = { intro: "The landscape narrows. Evidence from every prior field converges on the pass. Only a few paths remain. We compare candidate cruxes one at a time.", pivotalReminder: "Which challenge, if solved, makes the others easier?", candidates: [ { id: "c1", rank: 1, from: "Promising science", to: "Partner-ready infrastructure", why: "Captures the real buyer question. Partners adopt when a technology improves the fate of their program — not because it is elegant.", crit: "Less inspiring than “curing T1D,” but more strategic.", recommended: true }, { id: "c2", rank: 2, from: "Best cells", to: "Best product format", why: "Uses ImmunoShield’s strongest line. A strong market narrative.", crit: "Still needs proof that partners agree." }, { id: "c3", rank: 3, from: "T1D cure story", to: "Eligibility expansion", why: "Ties to “cure for some — not for most” and the 300K→1.8M thesis.", crit: "Overreaches unless eligibility is validated clinically and commercially." }, { id: "c4", rank: 4, from: "Device company", to: "De-risking company", why: "Supports the partner-readiness sprint, CMC audit, and FDA package.", crit: "May underplay the proprietary technology if used too bluntly." }, { id: "c5", rank: 5, from: "Competitor landscape", to: "Partner ecosystem", why: "Converts competitive pressure into strategic optionality.", crit: "Politically hard; rivals may prefer internal solutions." }, { id: "c6", rank: 6, from: "Tolerance breakthrough", to: "Macroencapsulation wedge", why: "Avoids forcing partners to believe the whole vision too early.", crit: "Could make the company look narrower if tolerance isn’t visible as upside." }, ], statement: "ImmunoShield’s crux is to prove that its spiral macroencapsulation platform is the fastest, least disruptive way for allogeneic cell-therapy developers to make their cells safer, retrievable, scalable, and partner-ready — before partners decide to build, buy, wait, or stay with immunosuppression.", moves: [ { n: "01", t: "Partner proof", d: "Secure an LOI, cells / data access, or paid feasibility." }, { n: "02", t: "CMC proof", d: "Produce a partner-facing manufacturing-integration map." }, { n: "03", t: "Regulatory proof", d: "Prepare the FDA INTERACT / Pre-IND question package." }, ], }; /* ---------- CONSTELLATION · Integration ---------- */ const INTEGRATION = { intro: "The room darkens. Nothing new appears — only relationships. The insights we gathered light up, and the lines between them become visible.", truth: "Praise is not proof. Interest is not adoption. A meeting is not momentum.", stars: [ { id: "s1", label: "The crux is partner behavior", x: 22, y: 30, mag: 3, note: "Before every question, ask: what behavior would prove this?" }, { id: "s2", label: "Data must become decision-grade", x: 48, y: 22, mag: 2, note: "For every milestone: who changes what if this passes?" }, { id: "s3", label: "Lead with the wedge, preserve the upside", x: 70, y: 38, mag: 3, note: "Separate the macroencapsulation story from the tolerance story." }, { id: "s4", label: "Strategy is the smallest solvable crux", x: 36, y: 60, mag: 2, note: "Find one action that forces a real yes / no." }, { id: "s5", label: "Competitors may become customers", x: 80, y: 66, mag: 1, note: "The market question is: how many of them might need us?" }, { id: "s6", label: "Value is created by uncertainty removal", x: 58, y: 74, mag: 2, note: "Not by claims. De-risk, then raise." }, ], links: [["s1","s2"],["s2","s3"],["s1","s4"],["s4","s6"],["s2","s5"],["s3","s5"],["s4","s2"]], identity: "I am now someone who looks past the elegance of the idea and asks what concrete behavior would prove the strategy is real.", closing: "The proof is partner behavior. A good meeting is not progress unless someone commits cells, budget, data, or a next step.", }; /* ---------- FRICTION GATES (between stages) ---------- */ const GATES = { // shown before entering target location id cartographer: { eyebrow: "BEFORE THE TABLE", q: "Which note most changed how you’re thinking?", opts: ["A cure for some — not for most.", "Winning = a better product format.", "Make competitors into partners.", "Retrievability lowers fear."] }, pass: { eyebrow: "BEFORE THE PASS", q: "Which observation most changed your thinking on this expedition?", opts: ["Eligibility is a product problem, not a cell problem.", "Value accrues to the enabling layer.", "Praise is not the same as commitment.", "De-risking is the thing being sold."] }, constellation: { eyebrow: "BEFORE THE CHAMBER", q: "To enter, you must abandon one idea you arrived with.", opts: ["“Better science will win on its own.”", "“A good meeting means momentum.”", "“We must prove the whole platform first.”", "“Competitors are only competitors.”"] }, }; window.ATLAS_DATA = { LOCATIONS, LISTENING, FRAMING, ENVISIONING, ASSUMPTIONS, TRANSFORMATION, CRUX, INTEGRATION, GATES };